J P Guastalla

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates

Cyrille B. Confavreux, A Fontana, J P Guastalla et al. · Bone · 2007 · 122 citations

Bone Disease, Bone Health, Gynecology +10

Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

T Bachelot, C. Bourgier, Claire Cropet et al. · Cancer Research · 2010 · 61 citations

Breast Oncology, Pharmacotherapy, Endocrine Oncology +16

A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.

M.-A. Mahé, P. Fumoleau, Michel Fabbro et al. · PubMed · 1999 · 59 citations

Surgical Oncology, Cancer Management, Gynecology +16

Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule

Godefridus J. Peters, M. Clavel, Paul Noordhuis et al. · Journal of Chemotherapy · 2007 · 42 citations